Related references
Note: Only part of the references are listed.Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Systemic lupus erythematosus one disease or many?
N. Agmon-Levin et al.
AUTOIMMUNITY REVIEWS (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus
M. U. Martinez-Martinez et al.
LUPUS (2011)
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Mary Anne Dooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus
Katsuya Suzuki et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Decreased Live Births in Women With Systemic Lupus Erythematosus
Evelyne Vinet et al.
ARTHRITIS CARE & RESEARCH (2011)
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
Frederic A. Houssiau et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
High-Dose Cyclophosphamide Versus Monthly Intravenous Cyclophosphamide for Systemic Lupus Erythematosus A Prospective Randomized Trial
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2010)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Nonrenal Disease Activity Following Mycophenolate Mofetil or Intravenous Cyclophosphamide as Induction Treatment for Lupus Nephritis
Ellen M. Ginzler et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Incidence of cancer among female patients with systemic lupus erythematosus in Korea
Kwi Young Kang et al.
CLINICAL RHEUMATOLOGY (2010)
Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice
H. Ogawa et al.
LUPUS (2010)
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE
Bridget Griffiths et al.
RHEUMATOLOGY (2010)
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
R. Kaiser et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study
Yoshie Kusunoki et al.
MODERN RHEUMATOLOGY (2009)
Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study
C. Nannini et al.
LUPUS (2009)
Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
J. D. Posalski et al.
LUPUS (2009)
Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII)
L. A. Gonzalez et al.
LUPUS (2009)
Seizures in patients with systemic lupus erythematosus:: data from LUMINA, a multiethnic cohort (LUMINA LIV)
R. M. Andrade et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Predictors of premature gonadal failure in patients with systemic lupus erythematosus.: Results from LUMINA, a multiethnic US cohort (LUMINA LVIII)
L. A. Gonzalez et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Steroid-Sparing Effects of Methotrexate in Systemic Lupus Erythematosus: A Double-Blind, Randomized, Placebo-Controlled Trial
Paul R. Fortin et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension
Olivier Sanchez et al.
CHEST (2006)
Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-Study
Karin Manger et al.
AUTOIMMUNITY REVIEWS (2006)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
EM Ginzler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Systemic lupus erythematosus in a multiethnic cohort (LUMINA):: XXVIII.: Factors predictive of thrombotic events
KT Ho et al.
RHEUMATOLOGY (2005)
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus
L Barile-Fabris et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Sequential therapies for proliferative lupus nephritis
G Contreras et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
LS Tam et al.
LUPUS (2004)
Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus
L Gonzalez-Lopez et al.
LUPUS (2004)
Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk
M Bijl et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
M Petri et al.
ARTHRITIS AND RHEUMATISM (2003)
Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)
L Stojanovich et al.
LUPUS (2003)
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents
MY Karim et al.
RHEUMATOLOGY (2002)
Immunosuppressive therapy in lupus nephritis -: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
FA Houssiau et al.
ARTHRITIS AND RHEUMATISM (2002)
Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus
GE Katsifis et al.
RHEUMATOLOGY (2002)
Critical illness in systemic lupus erythematosus and the anti phospholipid syndrome
FMK Williams et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus
V Noël et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Risk factors for ovarian failure in patients with systemic lupus erythematosus
MMC Medeiros et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2001)
Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study
CF Remer et al.
LUPUS (2001)
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
TM Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use
SJ Morton et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus
F Dammacco et al.
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH (2000)
Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A
F Conti et al.
LUPUS (2000)
Share Paper
